Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Autoimmune Thrombocytopenic Purpura Clinical Trial

Official title: Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Status Recruiting

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Clinical Trial Description

Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Autoimmune Thrombocytopenic Purpura
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombocytopenic, Idiopathic

• NCT number: NCT00107913
• Study type: Interventional
• Source: Hematology and Oncology Specialists
• Status: Recruiting
• Phase: Phase 2
• Start date: September 2001
• Completion date: April 2005